17 terminated. 17 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 17 |
| Phase 1 | 1 | Terminated 1 |
Follow Bone Marrow Neoplasms: new trials by email Literature Review of Bone Marrow Neoplasms trials Research Report on Bone Marrow Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera Idasanutlin - Polycythemia Vera | Phase 2 | Terminated | Hoffmann-La Roche | 27 | 2018-02-21 | 2021-12-08 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) Pacritinib, Busulfan, Questionnaires - Myeloproliferative Diseases | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2015-06-15 | 2018-10-30 |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment - Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2015-05-14 | 2019-05-15 |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Momelotinib - Polycythemia Vera, Essential Thrombocythemia | Phase 2 | Terminated | Sierra Oncology LLC - a GSK company | 39 | 2014-02-19 | 2020-04-20 |
| Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera Erlotinib - Polycythemia Vera | Phase 2 | Terminated | University of Oklahoma | 5 | 2009-12-01 | 2020-08-24 |
| Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis Dacogen - Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 4 | 2008-03-01 | 2015-12-30 |
| Dasatinib in Polycythemia Vera Dasatinib - Polycythemia Vera | Phase 2 | Terminated | Weill Medical College of Cornell University | 10 | 2007-04-30 | 2017-06-20 |
| A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma PXD101 - Multiple Myeloma | Phase 2 | Terminated | Valerio Therapeutics | 4 | 2007-03-01 | 2015-07-08 |
| Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers Darinaparsin - Hematologic Neoplasms, Bone Marrow Neoplasms | Phase 2 | Terminated | Alaunos Therapeutics | 50 | 2006-12-29 | 2026-10-01 |
| Azacitidine in Treating Patients With Myelofibrosis azacitidine - Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 10 | 2006-08-01 | 2011-04-21 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease anti-thymocyte globulin, cyclophosphamide, cyclosporine - Leukemia, Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 13 | 2005-11-01 | 2017-06-14 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis imatinib mesylate - Chronic Myeloproliferative Disorders | Phase 2 | Terminated | OHSU Knight Cancer Institute | 10 | 2005-08-01 | 2012-01-13 |
| Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML Total Body Irradiation, Fludarabine, Campath 1H - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Terminated | Baylor College of Medicine | 7 | 2001-12-01 | 2012-10-10 |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation anti-thymocyte globulin, busulfan, cyclophosphamide - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 1997-09-01 | 2012-12-11 | |
| Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia cyclophosphamide, cyclosporine, fludarabine phosphate - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 51 | 2013-05-01 |
Polycythemia Vera (15) · Myeloproliferative Disorders (11) · Primary Myelofibrosis (11) · Thrombocythemia, Essential (10) · Leukemia (4) · Leukemia, Myeloid, Acute (4) · Multiple Myeloma (4) · Myelodysplastic Syndromes (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myelomonocytic, Chronic (3) · Neoplasms, Plasma Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Refractory (2)
Hemic and Lymphatic Diseases (17) · Neoplasms (17) · Neoplasms by Site (17) · Bone Marrow Diseases (16) · Hematologic Neoplasms (16) · Hematologic Diseases (15) · Hemorrhagic Disorders (11) · Blood Coagulation Disorders (10) · Blood Platelet Disorders (10) · Thrombocytosis (9) · Neoplasms by Histologic Type (7) · Pathological Conditions, Signs and Symptoms (6) · Chronic Disease (5) · Disease Attributes (5)
fludarabine phosphate (5) · Cyclophosphamide (4) · Cyclosporine (3) · Whole-Body Irradiation (3) · Antilymphocyte Serum (2) · Busulfan (2) · Methylprednisolone (2) · Peripheral Blood Stem Cell Transplantation (2) · Radiotherapy (2) · Stem Cell Transplantation (2) · fludarabine (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Alemtuzumab (1) · Azacitidine (1) · Biological Therapy (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Alaunos Therapeutics (1) · Baylor College of Medicine (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Sierra Oncology LLC - a GSK company (1) · University of Oklahoma (1) · Valerio Therapeutics (1) · Weill Medical College of Cornell University (1)
United States (17) · Australia (2) · Canada (2) · France (1) · Germany (1) · Italy (1)
Ruben A. Mesa, MD (2) · Bipin N. Savani, MD (1) · Colleen Delaney, MD, MSC (1) · George Carrum, MD (1) · Michael Mauro, MD (1) · Mohamad Cherry, MD (1) · Peter Lee, MD, PhD (1) · Philip McCarthy, MD (1) · Richard T Slver, M.D. (1) · Srdan Verstovsek (1) · Steven C. Goldstein, MD (1) · Uday Popat, MD (1) · Uma Borate, MD (1)
P30CA015083 (2), 2017 (1), P30CA016672 (1), T32CA009515 (1)